Top Undervalued Stocks To Watch For 2019

As I mentioned earlier this week, the market has transformed from a straight shot moneymaking bull market machine into more of a runaway train headed for untested track in near-zero visibility conditions. Take what you know and throw it — along with most of your logic — out the window.

The best way to win now is to laser in on very unique stocks that are either undervalued or overvalued while trying to steer clear of unpredictable geopolitical policy shifts. (Honestly, it’s starting to feel like these shifts are occurring with higher frequency than the Twitter messages triggering them.)

In an effort to do just that, I searched for a stock that shouldn’t be terribly affected by tariffs… or walls… taxes… or the USPS.

As I scoured the markets for an “insulated play,” I landed on pizza. But unlike the rocket my Profit Amplifier subscribers and I rode in February with Domino’s Pizza (NYSE: DPZ) — which gave us a 22.5% return in only seven days — this new play is focused on a recent loser that is still extremely overvalued.

Top Undervalued Stocks To Watch For 2019: Identiv, Inc.(INVE)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    The Trade Desk, Inc. (NASDAQ: TTD) jumped 36.2 percent to $71.82 after the company reported upbeat results for its first quarter. The company also issued strong second-quarter and FY18 sales guidance.
    WideOpenWest, Inc. (NYSE: WOW) jumped 30.4 percent to $8.80 after the company reported Q1 results.
    MoSys, Inc. (NASDAQ: MOSY) shares surged 28.6 percent to $1.9541 after the company reported better-than-expected Q1 results and issued strong Q2 forecast.
    Boxlight Corporation (NASDAQ: BOXL) gained 24 percent to $6.39.
    Akcea Therapeutics, Inc. (NASDAQ: AKCA) shares gained 19.1 percent to $24.60. Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced that the Endocrinologic and Metabolic Drugs Advisory Committee, which met to discuss the safety and efficacy of subcutaneously injected volanesoren solution for patients with familial chylomicronemia syndrome, voted 12-8 to support its approval.
    Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) shares rose 17 percent to $10.31 after reporting Q3 results.
    ArcBest Corporation (NASDAQ: ARCB) gained 16.8 percent to $43.1457 after reporting upbeat quarterly earnings.
    Amtech Systems, Inc. (NASDAQ: ASYS) rose 16.2 percent to $8.60. Amtech posted Q2 earnings of $0.19 per share on sales of $32.783 million.
    Identiv, Inc (NASDAQ: INVE) surged 14.4 percent to $3.8450 following Q1 results.
    Omeros Corporation (NASDAQ: OMER) shares rose 14.3 percent to $18.43 following Q1 results.
    VivoPower International PLC (NASDAQ: VVPR) gained 11.5 percent to $2.71.
    Intersections Inc. (NASDAQ: INTX) gained 11.4 percent to $2.55 after reporting Q1 results.
    Noodles & Company (NASDAQ: NDLS) shares rose 10.9 percent to $8.65 following Q1 results.
    Voyager Therapeutics, Inc. (NASDAQ: VYGR) climbed 10.6 percent to $18.54 following Q1 results.
    Blink Charging Co. (NASDAQ: BLNK) rose 10.4 percent to $5.739.
    Immersion Corporation (NASDAQ: IMMR) gained 9.6 percent to $12.69

Top Undervalued Stocks To Watch For 2019: Invesco Trust for Investment Grade Municipals(VGM)

Advisors’ Opinion:

  • [By Max Byerly]

    Media headlines about Invesco Van Kmpn Trst Fr Invst Grd Mncpl (NYSE:VGM) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Invesco Van Kmpn Trst Fr Invst Grd Mncpl earned a news impact score of 0.19 on Accern’s scale. Accern also gave headlines about the investment management company an impact score of 46.4657191418091 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Top Undervalued Stocks To Watch For 2019: Santander Consumer USA Holdings Inc.(SC)

Advisors’ Opinion:

  • [By Jordan Wathen]

    Shares of subprime automotive lender Santander Consumer USA Holdings (NYSE:SC) are up by about 16% as of 11:35 a.m. EDT after the company announced earnings that were better than Wall Street expected. It earned $242 million, or $0.67 per diluted share, driven by higher loan originations, falling expenses, and declining provisions for loan losses in the first quarter.

  • [By Lisa Levin]

    Santander Consumer USA Holdings Inc. (NYSE: SC) shares were also up, gaining 14 percent to $17.89 following upbeat quarterly earnings.

    Equities Trading DOWN

  • [By Max Byerly]

    Santander Consumer USA Holdings Inc (NYSE:SC) was the recipient of some unusual options trading on Wednesday. Stock traders bought 12,151 put options on the company. This represents an increase of approximately 1,275% compared to the typical daily volume of 884 put options.

  • [By Lisa Levin]

    Santander Consumer USA Holdings Inc. (NYSE: SC) shares were also up, gaining 16 percent to $18.275 following upbeat quarterly earnings.

    Equities Trading DOWN

  • [By Lisa Levin] Gainers
    Check-Cap Ltd. (NASDAQ: CHEK) shares jumped 104.82 percent to close at $14.87 on Tuesday.
    EVINE Live Inc. (NASDAQ: EVLV) rose 31.25 percent to close at $1.06. The pay-TV home shopping company was named as a potential acquisition target by TechCrunch. According to the publication, Amazon.com, Inc. (NASDAQ: AMZN) is exploring ways of marketing its products and services to consumers beyond the internet.
    SemiLEDs Corporation (NASDAQ: LEDS) shares climbed 27.16 percent to close at $4.26 on Tuesday.
    Atossa Genetics Inc. (NASDAQ: ATOS) gained 27.09 percent to close at $3.80. Atossa Genetics disclosed that it has Received positive interim review from the Independent Safety Committee in Phase 1 Topical endoxifen dose escalation study in men.
    Heidrick & Struggles International, Inc. (NASDAQ: HSII) surged 17.13 percent to close at $37.95 as the company posted upbeat results for its first quarter.
    Santander Consumer USA Holdings Inc. (NYSE: SC) shares gained 15.91 percent to close at $18.21 following upbeat quarterly earnings.
    Riot Blockchain, Inc. (NASDAQ: RIOT) shares jumped 15.73 percent to close at $7.58 on Tuesday after declining 1.50 percent on Monday.
    Sanmina Corp (NASDAQ: SANM) shares gained 14.62 percent to close at $31.75 as the company reported stronger-than-expected earnings for its second quarter on Monday.
    Orchids Paper Products Company (NYSE: TIS) jumped 12.86 percent to close at $7.37. Orchids Paper Products is expected to report its Q1 financial results on Wednesday, April 25, 2018.
    Helix Energy Solutions Group, Inc. (NYSE: HLX) rose 12.8 percent to close at $7.05 following strong quarterly results.
    Avid Bioservices, Inc. (NASDAQ: CDMO) rose 12.72 percent to close at $3.81.
    Genprex, Inc. (NASDAQ: GNPX) gained 12.61 percent to close at $5.00.
    Obalon Therapeutics, Inc. (NASDAQ: OBLN) rose 12.39 percent to close at $3.72.
    NextDecade Corporation (NASDAQ: NEXT) shares climbed 11.88 percent to close at $7

Top Undervalued Stocks To Watch For 2019: Integrated Device Technology, Inc.(IDTI)

Advisors’ Opinion:

  • [By Ezra Schwarzbaum]

    Several other optics stocks stand to gain. In a Monday note, Bank of America Merrill Lynch analyst Vivek Arya also highlighlited the semiconductor space as one that could benefit from the news. Other stocks to watch include:

    Lumentum Holdings Inc (NASDAQ: LITE)
    Ciena Corporation (NYSE: CIEN)
    Coherent, Inc. (NASDAQ: COHR)
    II-VI, Inc. (NASDAQ: IIVI)
    Inphi Corporation (NYSE: IPHI)
    Skyworks Solutions Inc (NASDAQ: SWKS)
    Integrated Device Technology Inc (NASDAQ: IDTI)
    Qorvo Inc (NASDAQ: QRVO)
    Xilinx, Inc. (NASDAQ: XLNX)
    Broadcom Inc (NASDAQ: AVGO)

    Related Links:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Integrated Device Technology (IDTI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Integrated Device Technology (NASDAQ:IDTI) had its target price lifted by KeyCorp from $37.00 to $39.00 in a research note published on Thursday morning. KeyCorp currently has an overweight rating on the semiconductor company’s stock. KeyCorp also issued estimates for Integrated Device Technology’s Q2 2019 earnings at $0.37 EPS, Q3 2019 earnings at $0.39 EPS, Q4 2019 earnings at $0.37 EPS and FY2019 earnings at $1.47 EPS.

  • [By Stephan Byrd]

    Envestnet Asset Management Inc. reduced its stake in shares of Integrated Device Technology (NASDAQ:IDTI) by 71.2% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 7,410 shares of the semiconductor company’s stock after selling 18,353 shares during the period. Envestnet Asset Management Inc.’s holdings in Integrated Device Technology were worth $226,000 at the end of the most recent reporting period.

Top Undervalued Stocks To Watch For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Keith Speights]

    Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiranappears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs.

  • [By Max Byerly]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

  • [By Sean Williams, Chuck Saletta, and Brian Feroldi]

    So, which biotech stocks should you consider buying in June? That’s a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).

  • [By Joseph Griffin]

    BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

Leave a Reply

Your email address will not be published. Required fields are marked *